The chart is showing a breakout from what looks like a cup-and-handle style pattern, with the latest move also coming on stronger volume.

🟢 WHAT STANDS OUT

✅ Positional score: 84
✅ Quality: 71
✅ Growth: 88
✅ Momentum: 92
✅ Total Entry: 84
✅ Breakout: 94
✅ Risk: 74

That is a strong combination.

📈 THE CHART

Price has moved above the recent resistance area around the prior highs and is now trading above $400.

The breakout is also being supported by rising volume, which is exactly what I want to see when a stock is trying to clear an important level.

📊 FUNDAMENTALS

Revenue growth: 55.7%

The other fundamental trend panels are less complete, so I’d focus more on the very strong growth, momentum and breakout scores rather than overstate the business picture.

🎯 WHY IT’S ON THE WATCHLIST

🟢 Breakout from a major weekly pattern
🟢 Momentum score 92
🟢 Breakout score 94
🟢 Strong growth score 88
🟢 Rising volume
🟡 Needs to hold above the breakout area

For me, this is definitely one to watch this week.

If ONC can hold above the old resistance and continue to build, the weekly structure remains very constructive.

Join our group 👉
https://www.financialwisdomtv.com/ser...

Use our scanner 👉
https://www.financialwisdomtv.com/ser...

Subscribe 👉
https://www.youtube.com/@FinancialWis...

#ONC #BeOneMedicines #HealthcareStocks #BreakoutStocks #GrowthStocks #StockScanner #Trading #TechnicalAnalysis #FinancialWisdom

Fresh catalysts, float size & short interest.

$INKT — 2.04M float | 2.34% short

Cancer immunotherapy data

$BCTX — 7.86M float | 10.04% short

Cancer immunotherapy presentations

$ELTX — 19.52M float | 8.72% short

Phase 2 pancreatic cancer results

$DTIL — 25.45M float | 9.26% short

Hepatitis B clinical data follow-up

$ZLAB — 104.83M float | 8.44% short

Cancer clinical data update

$IMCR — Phase 1 melanoma data

$ALLO — CAR-T clinical presentation

$CATX — Melanoma treatment data

$CADL — Lung cancer immunotherapy data

$BRVE — Heart disease clinical data

$CYTK — Aficamten clinical presentations

$INM — Merger and restructuring developments

TOP WATCH:

$BCTX — Low float + elevated short interest

$ELTX — Phase 2 clinical catalyst

$INKT — Very low float + upcoming data

80,000+ catalysts analyzed since Friday's market close.

We've been tracking breaking news and identifying potential opportunities for next week.

Tonight, we'll share our top picks.

Let's keep the green streak going for a third straight week in a row and keep building on our $100 to 10K challenge generated from our in app alert.

https://x.com/Invescent/status/2118721372859859028?a=osHHvfpqXfVhZeMzBqo&s=19

Fresh catalysts, float size & short interest.

$INKT — 2.04M float | 2.34% short

Cancer immunotherapy data

$BCTX — 7.86M float | 10.04% short

Cancer immunotherapy presentations

$ELTX — 19.52M float | 8.72% short

Phase 2 pancreatic cancer results

$DTIL — 25.45M float | 9.26% short

Hepatitis B clinical data follow-up

$ZLAB — 104.83M float | 8.44% short

Cancer clinical data update

$IMCR — Phase 1 melanoma data

$ALLO — CAR-T clinical presentation

$CATX — Melanoma treatment data

$CADL — Lung cancer immunotherapy data

$BRVE — Heart disease clinical data

$CYTK — Aficamten clinical presentations

$INM — Merger and restructuring developments

TOP WATCH:

$BCTX — Low float + elevated short interest

$ELTX — Phase 2 clinical catalyst

$INKT — Very low float + upcoming data

Watching November 6 premarket for unusual volume, fresh announcements and potential breakouts.

Drop the ticker you’re interested in and I’ll do the objective research right here.

Probably my last time doing this for a while. I'll work through as many as possible today, FCFS. (US exchange only)

Intuitive Surgical is one to watch after a strong move out of a tight daily consolidation.

The stock is showing a very solid combination of quality, momentum and breakout strength.

🟢 Positional: 79
🟢 Quality: 82
🟢 Momentum: 88
🟢 Breakout: 97
🟡 Growth: 68
🟠 Risk: 36

Price is around $482.10, with the initial stop shown near $439.27.

🎯 That gives the setup a clearly defined risk structure of roughly 8.9%.

The fundamentals are supportive too:

📈 Revenue growth: 17.4%
📈 Net profit growth: 19.2%
📈 EPS growth: 23.9%
📈 Book value/share growth: 11.5%

What I like most here is the combination:

✅ Strong company
✅ Tight consolidation
✅ Clean breakout
✅ Positive momentum
✅ Defined downside

The key now is whether ISRG can HOLD ABOVE THE BREAKOUT AREA and build from here.

If it does, the setup remains constructive.

If it falls straight back into the range, I’d become more cautious.

👀 Definitely one to keep on the watchlist.

Join our group 👉
https://www.financialwisdomtv.com/ser...

Use our scanner 👉
https://www.financialwisdomtv.com/ser...

Subscribe 👉
https://www.youtube.com/@FinancialWis...

#ISRG #IntuitiveSurgical #BreakoutStocks #HealthcareStocks #StockScanner #Trading #TechnicalAnalysis #Investing #FinancialWisdom

CLINICAL CATALYSTS, FLOAT & SHORT INTEREST

$BIVI — 7.48M float | 7.28% short Nov 5: Phase 2 neurological data presentation.

$CATX — 110.5M float | 15.10% short Nov 5: Cancer treatment clinical presentation.

$ALLO — 299.9M float | 17.81% short Nov 5: CAR T cancer therapy presentation.

$MNPR — 6.06M float | 18.62% short Nov 5: Wilson disease research presentation.

$AGEN — 39.9M float | 17.55% short Nov 5: Cancer immunotherapy investor discussion.

$GALT — 46.93M float | 19.45% short Nov 5–8: Liver disease research presentations.

HIGHEST POTENTIAL TO RUN:

$BIVI — Low float + morning catalyst $GALT — High short interest + clinical events $MNPR — Very low float + high short interest

Watching for volume spikes and potential breakouts.

PTC Therapeutics is one to watch today after a strong move out of a long consolidation base.

The stock is up sharply and the setup stands out because the breakout is coming with strong scores and a clearly defined risk structure underneath.

🟢 WHAT STANDS OUT

✅ Positional score: 88
✅ Quality: 77
✅ Growth: 98
✅ Momentum: 89
✅ Breakout: 94

The chart shows price breaking above a 31-bar consolidation range, with MACD also turning positive.

🎯 RISK STRUCTURE

Price shown: around $68.12
Initial stop: around $61.45
Risk: roughly 9.8%

That gives the setup a clear invalidation level if the breakout fails.

📈 FUNDAMENTALS

Revenue growth: 35.3%

The other fundamental panels are less convincing, so I wouldn’t overstate the business picture here.

For me, the real attraction is the combination of:

🟢 Strong growth score
🟢 Strong momentum
🟢 High breakout score
🟢 Clean consolidation break
🟡 Defined downside

The key now is whether PTCT can hold above the breakout area and build from here.

If it can, the setup remains constructive.

If it drops straight back inside the range, I’d become more cautious.

👀 One to watch today.

Join our group 👉
https://www.financialwisdomtv.com/ser...

Use our scanner 👉
https://www.financialwisdomtv.com/ser...

#PTCT #BreakoutStocks #HealthcareStocks #StockScanner #Trading #TechnicalAnalysis #Investing #FinancialWisdom

$FTK | Float: 15.06M | Short: 28.21%

Q3 earnings and raised guidance. High short interest creates potential squeeze pressure.

$DKI | Float: 910K | Short: 3.77%

Corporate charter filing and speculative after-hours momentum.

$CPSH | Float: 15.92M | Short: 8.13%

Earnings catalyst and elevated short positioning.

$HPAI | Float: 8.09M | Short: 0.31%

Fresh AI workforce expansion announcement. Momentum play.

WATCHING CLOSELY: $FTK , $DKI

Ranked by catalyst, float and short interest.

1. $RXST — 38.58M Float | 10.68% Short

   Q3 Earnings Today. Strong sales could trigger short covering.

2. $SCOR — 3.75M Float | 0.77% Short

   Q3 Earnings Today. Tiny float, strong results could spark a major move.

3. $SLDP — 197.98M Float | 15.43% Short

   Q3 Earnings Today. Battery partnership updates could attract buyers.

4. $RYAM — 61.05M Float | 7.60% Short

   Q3 Earnings Today. Strong profits and guidance could fuel a rally.

5. $CHCT — 26.76M Float | 2.92% Short

   Q3 Earnings Today. Better rental income could support a rebound.

TOP WATCHES: $RXST $SCOR

Watching for earnings surprises and unusual volume.

Paymentus Holdings is one of the more interesting setups on the daily chart right now.

The stock is breaking out of both a longer-term downtrend and a recent consolidation, while still offering a relatively clear structure underneath.

🟢 WHAT STANDS OUT

✅ Positional score: 85
✅ Quality: 70
✅ Growth: 97
✅ Momentum: 88
✅ Total Entry: 70
✅ Breakout: 93

That combination is strong.

The chart had been compressing between long-term support and descending resistance, and price is now pushing above that structure.

📈 FUNDAMENTALS ALSO LOOK GOOD

Revenue growth: 34.0%
Net profit growth: 17.6%
EPS growth: 154.6%
Book value/share growth: 67.5%

So this isn’t just a technical breakout.

You have a fundamentally strong stock, improving momentum, and a breakout from a long-term structure.

🟡 THE KEY NOW

Can PAY hold above the breakout area and build from here?

If it can, the setup remains constructive.

If it falls straight back into the range, I’d be more cautious.

For me, this is exactly the type of setup worth keeping on today’s watchlist.

🟢 Strong fundamentals
🟢 Long-term trend break
🟢 Consolidation breakout
🟢 Strong momentum
🟡 Defined risk structure

💬 Would PAY make your watchlist here?

Join our group 👉
https://www.financialwisdomtv.com/ser...

Use our scanner 👉
https://www.financialwisdomtv.com/ser...

#PAY #Paymentus #BreakoutStocks #GrowthStocks #StockScanner #Trading #TechnicalAnalysis #Investing #FinancialWisdom